Alterman A L, Fornabaio D M, Stackpole C W
J Natl Cancer Inst. 1985 Oct;75(4):691-702.
The progressive metastatic spread from subcutaneous transplants of two subpopulations of the mouse B16 melanoma, slow-growing clone G3.5 and fast-growing clone G3.12, was examined during tumor growth in C57BL/6 mice and after surgical excision of tumors of various sizes. In addition to enumeration of visible and lethal or potentially lethal ("clinically relevant") metastases, the occurrence of visibly undetectable proliferating (occult) or nonproliferating (dormant) micrometastases was assessed by implanting lymph nodes and organs subcutaneously into normal mice and monitoring for resulting tumor growth. Occult or dormant metastases were disseminated initially to the lungs from G3.5 tumors of 3-4 mm in mean geometric diameter (MGD) and G3.12 tumors of 6-7 mm in MGD. The ipsilateral axillary lymph node (IALN), the regional draining lymph node for these tumors, received metastases after the lungs, initially from 10 to 12-mm tumors. Subsequently, occult or dormant and visible metastases first appeared in systemic organs and lymph nodes (kidneys, adrenal glands, ovaries, and contralateral axillary lymph node) at tumor sizes of about 26 mm in MGD. Systemic metastases occurred only in mice with large and numerous lung metastases and did not depend on the continuing presence of the subcutaneous tumor or on the presence of IALN metastases, which indicated that established lung metastases were a generalizing site from which systemic metastatic spread initiated. After tumor excision, death generally resulted from extensive lung metastasis. Occasional lethal or clinically relevant metastases were also observed in the IALN, kidneys, adrenal glands, ovaries, brain, eyes, and urinary bladder; liver involvement was evident exclusively as occult or dormant micrometastases. Terminal metastatic patterns of these B16 melanoma transplants were as widespread and indiscriminate as those of malignant melanoma in humans.
在C57BL/6小鼠的肿瘤生长过程中以及对不同大小肿瘤进行手术切除后,研究了小鼠B16黑色素瘤两个亚群(生长缓慢的克隆G3.5和生长快速的克隆G3.12)皮下移植瘤的渐进性转移扩散情况。除了对可见的、致死性或潜在致死性(“临床相关”)转移灶进行计数外,还通过将淋巴结和器官皮下植入正常小鼠并监测由此产生的肿瘤生长情况,来评估明显不可检测的增殖性(隐匿性)或非增殖性(休眠性)微转移灶的发生情况。隐匿性或休眠性转移灶最初从平均几何直径(MGD)为3 - 4毫米的G3.5肿瘤和MGD为6 - 7毫米的G3.12肿瘤扩散至肺部。同侧腋窝淋巴结(IALN)是这些肿瘤的区域引流淋巴结,在肺部之后接收转移灶,最初来自直径为10至12毫米的肿瘤。随后,隐匿性或休眠性以及可见性转移灶首先在MGD约为26毫米的肿瘤大小的全身器官和淋巴结(肾脏、肾上腺、卵巢和对侧腋窝淋巴结)中出现。全身转移仅发生在有大量肺部转移灶的小鼠中,且不依赖于皮下肿瘤的持续存在或IALN转移灶的存在,这表明已形成的肺部转移灶是全身转移扩散起始的播散部位。肿瘤切除后,死亡通常由广泛的肺转移导致。在IALN、肾脏、肾上腺、卵巢、脑、眼和膀胱中也偶尔观察到致死性或临床相关转移灶;肝脏受累仅表现为隐匿性或休眠性微转移灶。这些B16黑色素瘤移植瘤的终末期转移模式与人类恶性黑色素瘤一样广泛且无差别。